Advertisement

Topics

NantKwest Company Profile

21:29 EDT 23rd June 2018 | BioPortfolio

NantKwest (Nasdaq:NK) is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the body’s first line of defense due to the innate ability of NK cells to rapidly identify and destroy cells under stress, such as cancer or virally-infected cells.


News Articles [10 Associated News Articles listed on BioPortfolio]

Management tracks: Sanofi, NantKwest

NantKwest to Present at Jefferies 2018 Global Healthcare Conference

NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that Dr. Patrick Soon-Shiong, Chairman & CEO of NantKwest, wil...

NantKwest to Present at Upcoming Science & Medicine Conferences

NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that the company will be presenting at two science and medicine co...

NantKwest Names Sonja Nelson Chief Financial Officer

NantKwest, Inc. (Nasdaq: NK) today announced the elevation of Sonja Nelson, chief accounting officer for the company, to the role of Chief Financial Officer (CFO). This pres...

Das aussichtsreichere Biotech in der Zelltherapie: Medigene oder NantKwest?

Erste zellbasierte Krebsimmuntherapien sind in 2017 unter großem Applaus zugelassen worden und führten zur Übernahme von Kite Pharma durch Gilead Sciences (WKN:885823). Die deutsche Medigene (WKN:A...

NantKwest to Present at Upcoming Investment and Healthcare Conferences

NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell-based therapeutics company, today announced that the company will be presenting and conducting one-on-one meet...

NantKwest to Host 3rd Annual Investor/Analyst Day Highlighting a Record Number of 15 INDs Authorized in 2017 Covering 12 Tumor Types with First In-Human Clinical Data of Safety and Early Signs of Clinical Activity of the NANT Cancer Vaccine

NantKwest (NASDAQ: NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the human immune system using natural killer ...

NantKwest Inc NK Financial and Strategic SWOT Analysis Review [Report Updated: 09032018] Prices from USD $300

SummaryNantKwest Inc NantKwest, formerly Conkwest Inc, a subsidiary of NantWorks LLC, is a clinicalstage immunotherapy company which develops therapeutic treatments for cancer, infectious diseases, an...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [3 Associated Companies listed on BioPortfolio]

NantKwest

NantKwest (Nasdaq:NK) is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) ...

NantKwest, Inc.

NantKwest (Nasdaq:NK) is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) ...

NantKwest Inc.

NantKwest (Nasdaq:NK) is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) ...

More Information about "NantKwest" on BioPortfolio

We have published hundreds of NantKwest news stories on BioPortfolio along with dozens of NantKwest Clinical Trials and PubMed Articles about NantKwest for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of NantKwest Companies in our database. You can also find out about relevant NantKwest Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record